173 related articles for article (PubMed ID: 22706571)
41. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
42. Alteration of plasma total F2-isoprostanes before and after hemodialysis in end-stage renal disease patients.
Kim KM; Jung BH; Paeng KJ; Kim SW; Chung BC
Prostaglandins Leukot Essent Fatty Acids; 2004 May; 70(5):475-8. PubMed ID: 15062851
[TBL] [Abstract][Full Text] [Related]
43. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients.
Schaller G; Scheiber-Mojdehkar B; Wolzt M; Puttinger H; Mittermayer F; Hörl WH; Födinger M; Sunder-Plassmann G; Vychytil A
Kidney Int; 2005 Dec; 68(6):2814-22. PubMed ID: 16316358
[TBL] [Abstract][Full Text] [Related]
44. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.
Kuo KL; Hung SC; Wei YH; Tarng DC
J Am Soc Nephrol; 2008 Sep; 19(9):1817-26. PubMed ID: 18495964
[TBL] [Abstract][Full Text] [Related]
45. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
46. Elevated cardiac troponin T in hemodialysis patients receiving more intravenous iron sucrose.
Guz G; Sahinarslan A; Dhondt AW; Bagdatoglu O; Kavutcu M; Reis KA; Yalçin R; Bali M; Sindel S
Ren Fail; 2004 Nov; 26(6):663-72. PubMed ID: 15600258
[TBL] [Abstract][Full Text] [Related]
47. Antioxidant supplementation prevents exercise-induced lipid peroxidation, but not inflammation, in ultramarathon runners.
Mastaloudis A; Morrow JD; Hopkins DW; Devaraj S; Traber MG
Free Radic Biol Med; 2004 May; 36(10):1329-41. PubMed ID: 15110397
[TBL] [Abstract][Full Text] [Related]
48. Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients.
Ferraro B; Galli F; Frei B; Kingdon E; Canestrari F; Rice-Evans C; Buoncristiani U; Davenport A; Moore KP
Kidney Int; 2003 Jun; 63(6):2207-13. PubMed ID: 12753309
[TBL] [Abstract][Full Text] [Related]
49. Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation.
Toblli JE; Cao G; Rivas C; Giani JF; Dominici FP
Int J Cardiol; 2016 Jun; 212():84-91. PubMed ID: 27038710
[TBL] [Abstract][Full Text] [Related]
50. Trends in intravenous iron use among dialysis patients in the United States (1994-2002).
St Peter WL; Obrador GT; Roberts TL; Collins AJ
Am J Kidney Dis; 2005 Oct; 46(4):650-60. PubMed ID: 16183420
[TBL] [Abstract][Full Text] [Related]
51. Influence of vitamin C supplementation on oxidative and immune changes after an ultramarathon.
Nieman DC; Henson DA; McAnulty SR; McAnulty L; Swick NS; Utter AC; Vinci DM; Opiela SJ; Morrow JD
J Appl Physiol (1985); 2002 May; 92(5):1970-7. PubMed ID: 11960947
[TBL] [Abstract][Full Text] [Related]
52. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis.
Handelman GJ; Walter MF; Adhikarla R; Gross J; Dallal GE; Levin NW; Blumberg JB
Kidney Int; 2001 May; 59(5):1960-6. PubMed ID: 11318969
[TBL] [Abstract][Full Text] [Related]
53. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
54. Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients.
Smith KS; Lee CL; Ridlington JW; Leonard SW; Devaraj S; Traber MG
Lipids; 2003 Aug; 38(8):813-9. PubMed ID: 14577659
[TBL] [Abstract][Full Text] [Related]
55. The effect of iron-vitamin C co-supplementation on biomarkers of oxidative stress in iron-deficient female youth.
Khoshfetrat MR; Mohammadi F; Mortazavi S; Rashidi A; Neyestani T; Kalantari N; Esmaillzadeh A
Biol Trace Elem Res; 2013 Jun; 153(1-3):171-7. PubMed ID: 23686563
[TBL] [Abstract][Full Text] [Related]
56. Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease.
Raj DS; Dominic EA; Pai A; Osman F; Morgan M; Pickett G; Shah VO; Ferrando A; Moseley P
Kidney Int; 2005 Nov; 68(5):2338-44. PubMed ID: 16221238
[TBL] [Abstract][Full Text] [Related]
57. Plasma esterified F2-isoprostanes and oxidative stress in newborns: role of nonprotein-bound iron.
Signorini C; Perrone S; Sgherri C; Ciccoli L; Buonocore G; Leoncini S; Rossi V; Vecchio D; Comporti M
Pediatr Res; 2008 Mar; 63(3):287-91. PubMed ID: 18287967
[TBL] [Abstract][Full Text] [Related]
58. Sodium ferric gluconate (SFG) in complex with sucrose for IV infusion: bioequivalence of a new generic product with the branded product in healthy volunteers.
Baribeault D
Curr Med Res Opin; 2011 Aug; 27(8):1653-7. PubMed ID: 21714710
[TBL] [Abstract][Full Text] [Related]
59. F2-isoprostanes as a biomarker of oxidative stress in the mouse bladder.
Clayton DB; Stephany HA; Ching CB; Rahman SA; Tanaka ST; Thomas JC; Pope JC; Adams MC; Brock JW; Clark PE; Hayward SW; Matusik RJ; Milne GL
J Urol; 2014 May; 191(5 Suppl):1597-601. PubMed ID: 24679873
[TBL] [Abstract][Full Text] [Related]
60. Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin.
Anbu AT; Kemp T; O'donnell K; Smith PA; Bradbury MG
Acta Paediatr; 2005 Dec; 94(12):1738-41. PubMed ID: 16431410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
